Drug

Oxaliplatin

In clinical development

Emerging researchLate-stage developmentRising momentum

Also known as Diaminocyclohexane Oxalatoplatinum, Eloxatin, L-OHP, LOHP+8 more

Diaminocyclohexane Oxalatoplatinum, Eloxatin, L-OHP, LOHP, Oxalatoplatinum, Oxalatoplatin, Xaliplatin, oxaliplatine, oxaliplatino, (SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUM, PLATINUM, ((1R,2R)-1,2-CYCLOHEXANEDIAMINE-.KAPPA.N,.KAPPA.N')(ETHANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O2)-, (SP-4-2)-, oxaliplatinum.

RxNorm32592 ChEMBLCHEMBL414804 ATCL01XA03UNII04ZR38536J

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

Perioperative Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) for Treatment of Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: a Prospective, Multi-center, Phase II Study

Clinical trial2026-07-28Primary completion · ClinicalTrials.gov

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma

Clinical trial2026-07-27Results expected Q3 2029 · ClinicalTrials.gov

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

Clinical trial2026-07-24Results expected Q3 2027 · ClinicalTrials.gov

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma.

Clinical trial2026-07-20Results posted · ClinicalTrials.gov

Clinical trial2026-07-20Status changed to Completed · ClinicalTrials.gov

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Clinical trial2026-07-16Results expected Q4 2026 · ClinicalTrials.gov

A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator's Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Clinical trial2026-07-15Results expected Q1 2028 · ClinicalTrials.gov

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.

Research2024-03-13Journal for immunotherapy of cancer

NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Research2024-01-02JAMA network open

Next-generation therapies for pancreatic cancer.

Research2024-01-01Expert review of gastroenterology & hepatology

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors.

Research2023-11-09Oncoimmunology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Oxaliplatin

Aliases & brands

Diaminocyclohexane OxalatoplatinumEloxatinL-OHPLOHPOxalatoplatinumOxalatoplatinXaliplatinoxaliplatineoxaliplatino(SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUMPLATINUM, ((1R,2R)-1,2-CYCLOHEXANEDIAMINE-.KAPPA.N,.KAPPA.N')(ETHANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O2)-, (SP-4-2)-oxaliplatinum

RxNorm CUI

32592

ChEMBL ID

CHEMBL414804

ATC codes

L01XA03

UNII

04ZR38536J

Clinical trials

199 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

199

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 199

Early Phase 12Phase 122Phase 1 / 220Phase 2110Phase 2 / 37Phase 333Phase 43Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer

Unknown statusPH IVNanjing Chia-tai Tianqing Pharmaceuticaln=3202017

Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'

CompletedPH IVHoffmann-La Rochen=2052011

CONCEPT - Phase IV, Randomized, Prospective, Multicenter Comparison of Intermittent Schedule of Oxaliplatin Combined With FOLFOX/Bevacizumab vs Conventional Mode of Administration of FOLFOX/Bevacizumab + Neuroprophylaxis With Calcium/Magnesium for Optimization of First-Line Therapy of Metastatic Colorectal Cancer

TerminatedPH IVSanofin=1802007

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

RecruitingPH IIIKey trialJanssen Research & Development, LLCn=1,0002032

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

RecruitingPH IIIKey trialAstraZenecan=2,1302031

Recent completions

Trials that read out recently, adding to the completed evidence base.

CompletedPH IIIMerck Sharp & Dohme LLCn=8632026

A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

CompletedPH I/IIHoffmann-La Rochen=2142025

Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM): an Open Label, Prospective, Single Arm Clinical Trial

CompletedPH IISir Run Run Shaw Hospitaln=322025

Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma

CompletedPH I/IIBeiGenen=712024

Phase II Study on NIVolumab in Combination With FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced COloRectal Cancer RASm/BRAFm Patients

CompletedPH IIGruppo Oncologico Italiano di Ricerca Clinican=732024

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

CompletedPH IIIBeiGenen=6492024

Research activity

15 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20072024

Most influential

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

The New England journal of medicine · 2018 · 2,091 cites

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009 · 1,132 cites

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

The New England journal of medicine · 2009 · 938 cites

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2007 · 802 cites

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Annals of oncology : official journal of the European Society for Medical Oncology · 2011 · 564 cites

Preoperative Treatment of Locally Advanced Rectal Cancer.

The New England journal of medicine · 2023 · 330 cites

Related diseases

6 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Colorectal Neoplasms5 Pancreatic Neoplasms5 Neoplasm Metastasis3 Carcinoma, Pancreatic Ductal2 Colonic Neoplasms2 Rectal Neoplasms2

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Fluorouracil

Studied across 10 of the same disease areas as Oxaliplatin in the shared literature.

10 shared papers10 shared diseases

Leucovorin

Studied across 10 of the same disease areas as Oxaliplatin in the shared literature.

10 shared diseases7 shared papers

Irinotecan

Studied across 9 of the same disease areas as Oxaliplatin in the shared literature.

9 shared diseases6 shared papers

Deoxycytidine

Studied across 7 of the same disease areas as Oxaliplatin in the shared literature.

7 shared diseases3 shared papers

Gemcitabine

Studied across 7 of the same disease areas as Oxaliplatin in the shared literature.

7 shared diseases3 shared papers

Paclitaxel

Studied across 7 of the same disease areas as Oxaliplatin in the shared literature.

7 shared diseases2 shared papers

Camptothecin

Studied across 7 of the same disease areas as Oxaliplatin in the shared literature.

7 shared diseases1 shared paper

Capecitabine

Studied across 2 of the same disease areas as Oxaliplatin in the shared literature.

2 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials